Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  Cancer Research

• Publication date

  1988-09-01

• Fields of study

  Medicine

• Identifiers
  PMID 3261631
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Natural cell-mediated cytotoxicity in vitro and inhibition of tumor growth in vivo by murine lymphoid cells cultured with T cell growth factor (TCGF)

  2004cited by this paper
• Functional analysis of interleukin-2 in immune surveillance against brain tumors.

  1987cited by this paper
• Adoptive immunotherapy of cancer: accomplishments and prospects.

  1984cited by this paper
• Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

  1984cited by this paper
• Adoptive immunotherapy of cancer: accomplishments and prospects.

  1984cited by this paper
• Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin.

  1983cited by this paper
• Immunotherapy of a chemically-induced sarcoma in rats: characterization of the effector T cell subset and nature of suppression.

  1982cited by this paper
• In vitro growth of cytotoxic human lymphocytes. V. Generation of allospecific cytotoxic lymphocytes to nonimmunogenic antigen by supplementation of in vitro sensitization with partially purified T-cell growth factor.

  1982cited by this paper
• Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor

  1982cited by this paper
• With long-term lymphoid cell lines expanded in t cell growth factor.

  1982cited by this paper
• Lymphokine-activated killer cell phenomenon. Lysis of natural killer- resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

  1982cited by this paper
• Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas.

  1981cited by this paper
• Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

  1981cited by this paper
• Specific adoptive therapy of established leukemia with syngeneic lymphocytes sequentially immunized in vivo and in vitro and nonspecifically expanded by culture with Interleukin 2.

  1981cited by this paper
• Interferon as a mediator of human lymphocyte suppression

  1980cited by this paper
• The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors.

  1980cited by this paper
• Disappearance of the NK effect after explantation of lymphocytes and generation of similar nonspecific cytotoxicity correlated to the level of blastogenesis in activated cultures.

  1980cited by this paper
• Generation of cytotoxic lymphocytes to syngeneic tumors by using co-stimulator (Interleukin 2): in vivo activity.

  1980cited by this paper
• Revised nomenclature for antigen-nonspecific T cell proliferation and helper factors.

  1979cited by this paper
• Continuous culture of T cells cytotoxic for autologous human leukaemia cells

  1979cited by this paper
• Augmentation of human natural cell-mediated cytotoxicity by a soluble factor. I. Production of N-cell-activating factor (NAF).

  1978cited by this paper
• Studies on cytotoxicity generated in human mixed lymphocyte cultures. I. Time course and target spectrum of several distinct concomitant cytotoxic activities.

  1978cited by this paper
• Expression of human T-lymphocyte antigens by natural killer cells.

  1978cited by this paper
• Characterization of natural killer (NK) cells and killer (K) cells in human blood: Discrimination between NK and K cell activities

  1978cited by this paper
• Cytotoxic reactivity of human lymphocytes cultured in vitro.

  1977cited by this paper
• Characterization of cytotoxic human lymphocyte subpopulations: the role of Fc-receptor-carrying cells.

  1977cited by this paper
• Lymphocyte-mediated cytotoxicity against human allogeneic and autologous lymphoid targets after concanavalin A-activation of cytotoxic effector cells.

  1977cited by this paper
• Selective in vitro growth of T lymphocytes from normal human bone marrows.

  1976cited by this paper

• Cell therapy for brain tumors: The first 60 years.

  2026cites this paper
• Cell therapies against brain tumors: Clinical development and emerging prospects

  2025cites this paper
• Complex neural-immune interactions shape glioma immunotherapy.

  2025cites this paper
• Adoptive cell therapy for glioma

  2022cites this paper
• Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox

  2022cites this paper
• Adoptive Immunotherapy beyond CAR T-Cells

  2021cites this paper
• Assessment of the efficacy of passive cellular immunotherapy for glioma patients

  2020cites this paper
• CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy

  2019cites this paper
• Immunotherapy for pediatric brain tumors: past and present.

  2019cites this paper
• Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy

  2017cites this paper
• Prospect of Immunotherapy for Glioblastoma: Tumor Vaccine, Immune Checkpoint Inhibitors and Combination Therapy.

  2017cites this paper
• Biomarkers for glioma immunotherapy: the next generation

  2015cites this paper
• Immunobiology and immunotherapeutic targeting of glioma stem cells.

  2015cites this paper
• Neural immune modulation and immunotherapy assisted by focused ultrasound induced blood-brain barrier opening

  2015cites this paper
• Sensitization of Immune-Resistant Tumor Cells to CTL-Mediated Apoptosis via Interference at the Dysregulated NF-κB/Snail/YY1/PI3K/RKIP/PTEN Resistant Loop

  2015cites this paper
• A New Hope in Immunotherapy for Malignant Gliomas: Adoptive T Cell Transfer Therapy

  2014cites this paper
• Glioma Stem Cells and Immunotherapy for the Treatment of Malignant Gliomas

  2013cites this paper
• Clinical trials in cellular immunotherapy for brain/CNS tumors

  2013cites this paper
• Recent developments on immunotherapy for brain cancer

  2012cites this paper
• Drug delivery strategies for the treatment of malignant gliomas.

  2012cites this paper
• Clinical trials with immunotherapy for high-grade glioma.

  2012cites this paper
• Adoptive cell transfer therapy for malignant gliomas.

  2012cites this paper
• Cellular immunotherapy for high-grade glioma.

  2011cites this paper
• The Development of Sustained Release Formulation for Pharmaceutical Proteins based on Vesicular Phospholipid Gels

  2010cites this paper
• Experimental approaches for the treatment of malignant gliomas.

  2010cites this paper
• Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy.

  2009cites this paper
• Biological therapy of glioblastoma

  2009cites this paper
• Intralesional Lymphokine-activated Killer Cells as Adjuvant Therapy for Primary Glioblastoma

  2009cites this paper
• Neuro-oncology index and review (adult primary brain tumors)

  2006cites this paper
• Are Immunological Mechanisms Involved in Colon Cancer and Are They Possible Markers for Biotherapy Improvement?

  2006cites this paper
• Long-term survival in a young patient with anaplastic glioma

  2006cites this paper
• Local and regional immunotherapy of cancer with interleukin 2

  2005cites this paper
• Cyst fluid of glioma does not inhibit the killing action of lymphokine-activated killer (LAK) cellsin vitro

  2005cites this paper
• Interleukin-2 in cancer treatment: Disappointing or (still) promising? A review

  2005cites this paper
• New Delivery Approaches for Pediatric Brain Tumors

  2005cites this paper
• Immunotherapy of surgical malignancies.

  2004cites this paper
• Interleukin-2 therapy of cancer.

  2004cites this paper
• Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro

  2004cites this paper
• Intracavitary Placement of Autologous Lymphokine-Activated Killer (LAK) Cells after Resection of Recurrent Glioblastoma

  2004cites this paper
• T-Cell Adoptive Immunotherapy

  2004cites this paper
• Immunotherapeutic strategies for malignant glioma.

  2004cites this paper
• How does the immune system attack cancer

  2004cites this paper
• The Neurosurgeon as Local Oncologist: Cellular and Molecular Neurosurgery in Malignant Glioma Therapy

  2003cites this paper
• Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes.

  2003cites this paper
• Changes in the immunologic phenotype of human malignant glioma cells after passaging in vitro.

  2002cites this paper
• Title Generation of stimulated , lymphokine activated T killer ( T-LAK ) cells from the peripheral blood of normal donors and adult patients with recurrent glioblastoma

  2002cites this paper
• New strategy developments in brain tumor therapy.

  2001cites this paper
• Therapeutic Activity of NK Cells against Tumors

  2001cites this paper
• Adoptive immunotherapy for malignant brain tumors using human peripheral blood mononuclear cells activated by the Streptococcal preparation OK-432.

  2001cites this paper
• Systemic T-Cell Immunotherapy for Brain Tumors

  2001cites this paper
• Locoregional immunotherapy in cancer patients: review of clinical studies.

  2000cites this paper
• Locoregional immunotherapy in cancer patients: Review of clinical studies

  2000cites this paper
• Exploitation of immune mechanisms in the treatment of central nervous system cancer.

  2000cites this paper
• Brain Tumor Immunotherapy

  2000influential citation
• Effects of OK-432 on the proliferation and cytotoxicity of lymphokine-activated killer (LAK) cells.

  1999cites this paper
• Antitumor activity of killer cells stimulated with both interleukin-2 and interleukin-12 on mouse glioma cells.

  1999cites this paper
• Immunotherapy of malignant brain tumors in children and adults: from theoretical principles to clinical application

  1999influential citation
• Development of a routine analysis method for liposome encapsulated recombinant interleukin-2.

  1998cites this paper
• Cytokine-Based Gene Therapy for Brain Tumors

  1998cites this paper
• Systemic T cell adoptive immunotherapy of malignant gliomas.

  1998cites this paper
• Adoptive immunotherapy of intracranial tumors by systemic transfer of tumor-draining lymph node cells (Review).

  1997cites this paper
• Activated lymph node T cells for systemic adoptive immunotherapy of malignant glioma

  1997cites this paper
• Gene Therapy for Neurological Disorders and Brain Tumors

  1997cites this paper
• Effect of irradiation on transforming growth factor-β secretion by malignant glioma cells

  1997cites this paper
• Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas.

  1996cites this paper
• Transforming Growth Factor-β Inhibits Interferon-γ Secretion by Lymph okine-activated Killer Cells Stimulated with Tumor Cells

  1996cites this paper
• Intrathecal immunotherapy in CNS tumors disseminating via CSF: preliminary evaluation using different treatment schedules

  1996cites this paper
• Immunological Directives for Biotherapy Improvement in the Treatment of Colorectal Cancer

  1996cites this paper
• Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors

  1996cites this paper
• Biological and monoclonal antibody therapy for high-grade gliomas.

  1996cites this paper
• Secretion of Transforming Growth Factor-1 and -2 by Malignant Glioma Cells

  1995cites this paper
• Cytokines and tumors of the central nervous system.

  1995cites this paper
• Isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine-activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma

  1995cites this paper
• Improved long term survival after intracavitary interleukin‐2 and lymphokine‐activated killer cells for adults with recurrent malignant glioma

  1995cites this paper
• Liposomal Delivery of Peptides and Proteins

  1995cites this paper
• Cytokines and tumors of the central nervous system

  1995cites this paper
• Novel developments in liposomal delivery of peptides and proteins

  1995cites this paper
• Novel biologic therapies for malignant gliomas. Antiangiogenesis, immunotherapy, and gene therapy.

  1995cites this paper
• Local administration of 7 beta-hydroxycholesteryl-3-oleate inhibits growth of experimental rat C6 glioblastoma.

  1994cites this paper
• Inhibition of Tumor Necrosis Factor‐α and β Secretion by Lymphokine Activated Killer Cells by Transforming Growth Factor‐β

  1994cites this paper
• Immunotherapy of malignant gliomas.

  1994cites this paper
• Immunobiology of malignant astrocytomas.

  1994cites this paper
• Loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients

  1994cites this paper
• Locoregional immunotherapy with interleukin-2 in head and neck squamous-cell carcinoma: preclinical and clinical studies

  1994cites this paper
• The effect of intraportal mannitol on the short-term in vivo distribution of radiolabelled A-LAK cells in rats

  1994cites this paper
• Tolerance and cerebrospinal fluid pharmacokinetics of intrathecally administered human natural interleukin-2: a phase I trial.

  1993cites this paper
• Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) Lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA

  1993cites this paper
• Clinical Trials of Immunotherapy of Cancer Utilizing Cytotoxic Cells

  1993cites this paper
• Interleukin-2 and lymphokine activated killer (LAK) cells

  1993cites this paper
• Interleukin-2: Biological Activities and Clinical Relevance in Advanced Stage Human Cancer

  1993cites this paper
• The cellular immunotherapy of primary brain tumors.

  1992cites this paper
• Chemoimmunotherapy of cancer: cyclophosphamide-resistant tumour cells are equally sensitive as the original tumour cell population to local IL-2 immunotherapy.

  1992cites this paper
• Immunotherapy with Stimulated Autologous Lymphocytes in a Case of a Juvenile Anaplastic Glioma*

  1992cites this paper
• Clinical Trials with Local Administration of Lymphopoietic Growth Factors

  1992cites this paper
• Lymphohaematopoietic Growth Factors in Cancer Therapy II

  1992cites this paper
• Treatment of Primary Brain Tumours

  1992cites this paper
• Cytokines and cancer.

  1992cites this paper
• Antiproliferative cytokines secreted by lymphokine-activated killer cells stimulated with tumor cells.

  1992cites this paper
• Cancer immunotherapy: are the results discouraging? Can they be improved?

  1992cites this paper
• Immunotherapy with stimulated autologous lymphocytes in a case of a juvenile anaplastic glioma.

  1992cites this paper